Predictive value of CCL26 and CCR3 levels for prognosis assessment in children with <i>Mycoplasma pneumoniae</i> pneumonia treated with azithromycin.

ABSTRACT:

Background

Mycoplasma pneumoniae pneumonia (MPP), a prevalent form of community-acquired pneumonia (CAP) in schoolchildren, frequently results in persistent fever or complications in 15-25% of cases despite azithromycin treatment. This highlights the urgent need for novel biomarkers to identify high-risk cases. This study aims to investigate the predictive value of serum C-C motif chemokine ligand 26 (CCL26) and C-C chemokine receptor 3 (CCR3) levels for treatment prognosis in children with MPP receiving azithromycin therapy.

Methods

Clinical data of 205 pediatric MPP patients treated in our hospital from February 2023 to February 2025 were collected. Serum levels of CCL26, CCR3, interleukin-6 (IL-6), tumor necrosis factor-alpha (TNF-α), and D-dimer (DD) were measured

SUBMITTER: Ma L 

PROVIDER: S-EPMC12433130 | biostudies-literature | 2025 Aug

REPOSITORIES: biostudies-literature